IAIM
INMB icon

International Assets Investment Management’s INmune Bio INMB Stock Holding History

International Assets Investment Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-700
Closed -$12K – 1150
2021
Q1 		$12K Hold
700
– – ﹤0.01% 1494
2020
Q4 		$12K Buy
+700
New +$6.59K ﹤0.01% 1355

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

International Assets Investment Management's INMB Position: Q2 2021 in Review

International Assets Investment Management sold out of INmune Bio (INMB) in Q2 2021, closing a stake of 700 shares — an estimated $12K sold.

International Assets Investment Management first reported a position in INMB in Q4 2020 and held it in 2 quarters. The position peaked at $12K in Q1 2021. 41 funds tracked by Wall St. Rank hold INMB as of Q2 2021.

  • International Assets Investment Management reported no remaining INmune Bio position as of Q2 2021 after selling out during the quarter.
  • International Assets Investment Management sold 700 INmune Bio shares in Q2 2021, an estimated $12K.
  • International Assets Investment Management first reported a position in INmune Bio in Q4 2020 and held it in 2 quarters.
  • International Assets Investment Management's INmune Bio position peaked at $12K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held INmune Bio as of Q2 2021.

Based on International Assets Investment Management's 13F filing for Q2 2021, filed 14 Jul 2021.